Mycosis Fungoides clinical trials

Explore recruiting mycosis fungoides clinical trials.

Recruiting mycosis fungoides studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mycosis Fungoides trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Investigator Initiated, descriptive, proof-of-concept, open-label pilot study targeting the tumor microenvironment and skin barrier deficiency through JAK1/3 inhibition

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

Spain, Denmark, Italy, France, Germany, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.

France, Belgium, Spain, Poland, Italy, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Mycosis Fungoides trials by city

Mycosis Fungoides in Toronto Mycosis Fungoides in Vancouver Mycosis Fungoides in Montreal Mycosis Fungoides in Calgary Mycosis Fungoides in Edmonton Mycosis Fungoides in Ottawa Mycosis Fungoides in Winnipeg Mycosis Fungoides in Quebec City Mycosis Fungoides in Hamilton Mycosis Fungoides in Kitchener Mycosis Fungoides in London Mycosis Fungoides in Halifax Mycosis Fungoides in New York Mycosis Fungoides in Los Angeles Mycosis Fungoides in Chicago Mycosis Fungoides in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease